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Abstract
The de novo biosynthetic machinery for both sphingolipid and ergosterol production in yeast is localized in the endoplasmic
reticulum (ER) and Golgi. The interconnections between the two pathways are still poorly understood, but they may be
connected in specialized membrane domains, and specific knockouts strongly suggest that both routes have different layers
of mutual control and are co-affected by drugs. With the goal of shedding light on the functional integration of the yeast
sphingolipid-ergosterol (SL-E) pathway, we constructed a dynamic model of the ergosterol pathway using the guidelines of
Biochemical Systems Theory (BST) (Savageau., J. theor. Biol., 25, 365–9, 1969). The resulting model was merged with a
previous mathematical model of sphingolipid metabolism in yeast (Alvarez-Vasquez et al., J. theor. Biol., 226, 265–91, 2004;
Alvarez-Vasquez et al., Nature 433, 425–30, 2005). The S-system format within BST was used for analyses of consistency,
stability, and sensitivity of the SL-E model, while the GMA format was used for dynamic simulations and predictions. Model
validation was accomplished by comparing predictions from the model with published results on sterol and sterol-ester
dynamics in yeast. The validated model was used to predict the metabolomic dynamics of the SL-E pathway after drug
treatment. Specifically, we simulated the action of drugs affecting sphingolipids in the endoplasmic reticulum and studied
changes in ergosterol associated with microdomains of the plasma membrane (PM).
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Introduction
Sphingolipids and sterols constitute two of the major classes of
eukaryotic lipids. Although, for the most part, these two classes can
be studied metabolically and functionally in isolation, there is a
growing body of evidence to suggest more intimate connections
between the two. In particular, the two pathways are subject to
cross- and co-regulation under many conditions [1,2]. Moreover,
interactions between the two classes have been implicated in the
action and resistance to many anti-fungal agents. Indeed, of
particular therapeutic interest among the new classes of drugs are
those that affect the biosynthesis of ergosterol and complex
sphingolipids (CS) and those that have been proposed to require
the formation of sphingolipid/ergosterol microdomains that
constitute anchors for fundamental homeostatic fungal proteins
like Pma1p [3,4].
Because the ergosterol and sphingolipid pathways constitute
complex systems, it is difficult to predict with intuition alone the
effects of changes in one pathway on the operation of the other;
moreover, it is difficult to predict which specific steps could
provide most efficacious drug targets and what the sequelae of
alterations in particular enzyme activities could be. To achieve
sufficient understanding of the dynamic interactions between the
two biosynthetic pathways and their regulatory effects on the
formation and destruction of putative microdomains, it seems
necessary to work toward reliable mathematical and computa-
tional systems models. Such models may eventually help us
appreciate differences in the structure and function of membrane
microdomains of normal or cancer cells, and other pathological
conditions [5–7]. The models may also aid in interpreting the
dynamics of microdomains, which are presently investigated
mainly through visualization by optical microscopy with molecular
markers [8]. Furthermore, dynamic simulations of microdomains
may provide rational clues about drug-membrane interactions and
aid the development of therapeutic agents [9].
It should be noted that the existence of biological microdomains
in cells has not been firmly established, in contrast to the physical
demonstration of microdomains in experimental models of
membranes. In yeast, the plasma membrane has at least three
different domains, one containing a variety of solute transporters,
another with the plasma membrane H+-ATPase [10] and still
another with associated TOR complex 2 [11]. Studies using filipin
staining suggest that some plasma membrane (PM) microdomains
may be enriched in ergosterol [12], and since sterols and
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sphingolipids can form complexes in vitro, perhaps these domains
are also enriched in complex sphingolipids, and microdomain-
associated proteins, such as solute transporters, Pma1p, and
probably several glycosylphosphatidylinositols (GPI’s)-linked pro-
teins [13–15]. A possible regulator of the PM localization and
stability of Pma1 is the presence of very long chain fatty acids
associated with detergent-insoluble membranes (DIM). This was
recently demonstrated in yeast mutants unable to produce
complex sphingolipids but able to constitute functional Pma1p
DIM microdomains in association with alternative compensatory
very-long chains glycerolipids [16].
Any metabolic model of microdomain dynamics requires better
insights into the biosynthesis of sphingolipids and sterols. The
biosynthetic sterol route in fungi and vertebrates has been
described in the literature with different names, including the
mevalonate pathway [17,18], the isoprenoid route [19], or the
sterol biosynthetic pathway [20]. Throughout this paper, we
simply refer to this route as the ‘‘ergosterol pathway.’’ It is well
known that the ergosterol pathway is closely connected with
sphingolipid metabolism, which has important structural and
signaling functions in yeast and higher organisms (e.g., [1,2,21–
28]). The aim of our study is the elucidation of the combined
‘‘sphingolipid-ergosterol’’ (SL-E) system with a dynamic mathe-
matical model.
The ergosterol pathway is readily divided into two functional
parts, namely the heme-dependent and the heme-independent
sections (Fig. 1). The heme-independent route yields squalene,
while the heme-dependent route results in metabolites from
lanosterol to ergosterol [19,20]. The heme-dependent section
utilizes molecular oxygen as co-substrate for the epoxidation of
squalene by Erg1p and cytochrome hemoproteins, which are
involved in the key demethylation and desaturation reactions
[20,29]. Interestingly the sphingolipid hydroxylation through the
Sur2p also uses molecular oxygen, a shared feature with ergosterol
biosynthesis [30].
Cholesterol and ergosterol are the final products of the sterol
biosynthetic routes for mammalian and yeast cells, respectively.
These sterol end products are essential components of lipid
membranes, and their production is tightly regulated at multiple
cellular levels [31]. Indeed, ergosterol is the main sterol
component in the yeast plasma membrane, followed by other
sterols such as zymosterol, fecosterol, and episterol, which are
present in lower concentrations [32,33]. The importance of sterols
for yeast survival is evidenced by the large number of antifungal
compounds affecting this route [34,35]. Also, ERG11 knockouts
and strains with a non-functional Erg11p enzyme are non-viable
unless exogenous ergosterol is supplied in the medium [36]. By
contrast, strains with mutations occurring after the Erg6p step are
viable, as the sterol intermediates can migrate to the PM and
supplant the essential ergosterol functions; however, these mutants
display alterations in the sensitivity to drugs and stress situations
[1,36,37].
In this work, we construct and validate a mathematical model of
the biosynthetic ergosterol pathway in Saccharomyces cerevisiae and
integrate it with an existing sphingolipid-glycerolipid model that
was formulated with methods of Biochemical Systems Theory
(BST) [38,39]. The combined, validated SL-E model is used to
predict the metabolite dynamics of the system when key enzymes
of the pathway are affected by drugs.
A mathematical representation of the heme-dependent section
of the ergosterol pathway had been established previously with
methods of Metabolic Flux Analysis [40]; however, this approach
did not consider the heme-independent section, sub-pools of
ergosterol, or feedback regulations within the pathway. Radioac-
tive tracer experiments have suggested that these features are
important for the sterol and sterol-ester dynamics [41,42]. We
therefore revisit the flux model and reformulate it to include these
features.
Results
Sterol biosynthesis is localized in the ER [29] and the sterol and
sphingolipid pathways share acetyl-CoA as a building block for
fatty acyl and mevalonate formation, respectively (Figs. 1 and 2). It
is therefore clear where the ergosterol pathway and the earlier
sphingolipid model overlap and how they have to be integrated in
a mathematical model. We used for this integration purpose the
modeling framework of Biochemical Systems Theory [43–46],
which allows a maximal degree of flexibility, while requiring a
minimum of assumptions. The details of model design, assump-
tions, diagnostics, and analysis are presented in the Methods section
and Tables S1, S2, S3, S4, Materials S1 and S2, Equations S1, S2, S3,
S4, S5, S6.
Steryl-ester dynamics after perturbations in external
acetate
As a first analysis, the ability of the model to predict dynamic
changes in sterol metabolism was evaluated. Taylor and Parks
conducted [14C]-acetate bolus (Fig. 3A) and pulse-chase (Fig. 3D)
experiments quantifying the levels of de novo sterols and steryl-esters
produced during exponential growth and with glucose in the
medium [42]. For comparisons between the sterol and the steryl-
ester pools, they corrected the radioactive fatty acids incorporated
in the steryl-ester fraction by multiplying the counts per minute by
27/43. We executed simulations of this scenario (Figs. 3B, 3E, 4B,
and 5) by suppressing the incorporation of labeled palmitoyl-CoA
(L12) at the stage of steryl-esters (L33, L34, L35), which we achieved
by alteration of the steryl-ester synthase enzymes (X181, X183) (see
Equations S1, S2, S3, S4, S5, and S6 for details of this specific
implementation). When the labeled palmitoyl-CoA (L12) is
included as co-substrate for the formation of labeled steryl-esters,
the model indicates a moderate increase in the maximal amplitude
(MA) of the steryl-ester pools (simulation results not shown).
The SL-E model dynamics for sterols and steryl-esters after an
external acetate bolus (Fig. 3B) shows qualitative concordance with
the experimental results (Fig. 3A) at least for the middle
exponential and steady-state growth phases quantified in parallel
by Taylor and Parks (see Figs. 1B and 2A in ref [42]). Both the
experiments and simulations reproduce the increase and slow
decrease in the steryl-ester pool.
Fig. 3E represents the SL-E model dynamics for sterol and
steryl-ester when the model is perturbed with an external acetate
pulse-chase (Fig. 3F). The simulations (Fig. 3E) show qualitative
concordance with Taylor and Parks’ experiments (Fig. 3D), at least
in the early phase of the experiment.
Fig. 4A represents the dynamics of CS, following a simulated
30-min labeled acetate pulse-chase bolus, as shown in Fig. 3F.
Even that they are not directily compared, because the radioactive
labeling is different, the MAs of inositol phosphorylceramide (IPC,
X20), mannosylinositol phosphorylceramide (MIPC, X21), and
mannosyldiinositol phosphorylceramide (M(IP)2C, X22) exhibit
the same order rank to those reported for a 30-min [2-3H]-inositol
pulse-chase experiment [47] during exponential growth. In the
simulation (Fig. 4B), the inner PM (X39) shows an early increase
which is probably due to the contribution of the flux through
Yeh2p (X182). The CS ergosterol pool (X37) increases mostly as a
consequence of the external acetate label, given as a pulse-chase as
in Fig. 3F. Ergosterol-ester sub-pool-1 (X35) is the steryl-ester with
Ergosterol Pathway Mathematical Modeling in Yeast
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the early sustained increase, while the steryl-ester in close contact
with the PM (X40) shown a latter sustained increase. The outer PM
ergosterol (X36) is not represented because of its low value. The
Steryl Lanosterol (X33) and Steryl Zymosterol (X34) present an
initial rise and posterior plateau starting in 700 min. At the end of
the simulation the Steryl Lanosterol (X33) and Steryl Zymosterol
(X34) present higher values than the Steryl Ergosterols pools (X35
and X40) (dynamics not shown).
The SL-E model is available in PLAS [48] and MatlabH [49]
codes in Materials S3 and S4 and Materials S5 and S6 respectively.
Table S11 presents the PLAS [48] into MatlabH [49] conversion
equivalence for the SL-E model dependent variables, pyruvate,
external acetate, and palmitate.
Effects of drugs on the SL-E pathway
In order to predict the sterol and steryl-ester dynamics when key
sphingolipid biosynthetic enzymes are impaired, the effects of
specific drugs affecting enzymes of the sphingolipid biosynthetic
route were decreased by 99% in their specific activities. In the first
analysis, we decreased IPC synthase (X133) activity, emulating a
pathway block exerted by drugs such as aureobasidin, galbonolide,
or khafrefungin [50]. Figs. 5A and 5B present the dynamics of
sterols and steryl-esters, as well as other intermediate metabolites,
in the SL-E model with reduced IPC synthase activity (X133) for a
30-min external labeled acetate pulse-chase perturbation. The
knockout conditions and posterior perturbations where done with
one minute of difference assuming the drug have reached their
enzyme site of action after that time. The comparison of Fig. 5A
with Fig. 3E (control) indicates that the sterols and the steryl-ester
pools are not affected by the decreased IPC synthase activity.
The comparison of ergosterol sub-populations in Figs. 4B and
5B shows that the decrease in the IPC synthase activity produces a
75% decrease in the MA of ergosterol associated with CS (X37).
This suggests that the vesicular co-transport of ergosterol and CS is
principally responsible for the decrease in CS ergosterol (X37). The
inner PM ergosterol (X39) presents an MA increase of 14% which
indicates a redistribution of the ergosterol from the outer to the
inner PM leaflet. Pools not predominantly affected by a decreased
IPC synthase activity are: ergosterol-ester-1 (X35), ergosterol-ester-
2 (X40), the endoplasmic reticulum ergosterol (X32), and the outer
PM ergosterol not associated with DIMs (X36) (not shown).
The second set of simulations involved drugs such as myriocin,
which inhibit serine palmitoyltransferase (SPT; X157) [50]. Figs. 5C
and 5D show the effects of the corresponding perturbation in the
SL-E model, which was implemented in a fashion similar to the
experiment in Fig. 3F. When comparing Figs. 5C and 5D with
their respective controls (Figs. 3E and 4B), three aspects stand out.
First, the sterol and steryl-ester dynamics take more time for
recovery from the pulse-chase perturbation. Second, between
Fig. 5C and Fig. 3E, there is a significant increase in the sterol-
ester pool. Third, between Fig. 5D and Fig. 4B, the MA of the CS-
associated ergosterol pool (X37) decreases by 63%. As in the case of
IPC synthase inhibition, much of this decrease in the CS-
associated ergosterol pool (X37) can be explained by the impaired
contribution of the vesicular transport of ergosterol and CS from
this pool. Fourth, there is a 43% increase in MA of ergosterol at
the inner side of PM (X39), which reflects the ergosterol
redistribution dynamics inside the PM when the ergosterol
associated with the CS is impaired. This increase is qualitatively
consistent with the increase in free ergosterol in PM under lcb1-
100 conditions in Bauman’s model (see Fig. 4B in ref [25]). To our
knowledge, this increase at the inner leaflet of the PM has not been
experimentally tested for Saccharomyces cerevisiae, and it seems
difficult to validate the model result because it is not easy to
quantify lipids within lipid rafts. Some technologies have been
developed to analyze larger detergent resistant structures and to
quantify lipids at the inner and outer leaflets of mammalian cells
[51–53], but, in spite of recent progress [54], a crisp lipid
characterization of rafts in yeast is still no possible. Fifth, the
endoplasmic reticulum ergosterol (X32) increased slightly (Figs. 5D
vs. 4B) as predicted by Baumann’s model (see Fig. 4B in ref [25]).
The modest 26% increase in ER ergosterol (X32) from Fig. 5D
vs Fig. 4B is in accordance with the difficulty to visualize the
intracellular ER ergosterol redistribution for lcb1-100 strains at
restrictive temperatures by fluorescent filipin-stained sterols [25].
Specifically, Baumann and collaborators recorded, for lcb1-100
strains at a restrictive temperature, an increase in the intracellular
ergosterol as detected by the fluorescent ergosterol-binding protein
filipin, but they were unable to visualize a change in the
endoplasmic reticulum filipin staining pattern. In addition, they
observed a slower equilibration rate for the ER-PM [3H]-
ergosterol in lcb1-100 strains at both permissive and restrictive
temperatures. This slower ER ergosterol (X32) recovery dynamics
can also be observed in our simulation (Fig. 5D vs. 4B). Baumann
and collaborators proposed that this slower lcb1-100 recovery is to
be expected for a non-vesicular ergosterol flux transport, which in
the wild type strain is already at maximal capacity. However the
lcb1-100 ergosterol redistribution, based solely on the filipin-
stained results, needs to be taken with caution because of recent
reports that filipin principally stains ergosterol not associated with
sphingolipids [55].
In summary, the modified SL-E model with reduced SPT
activity (X157) shows a rise in the PM inner ergosterol (X39) and ER
ergosterol (X32), a decrease in the PM outer ergosterol associated
with the complex sphingolipids (X37), and a general slower
recovery dynamics, which can be explained as a consequence of
the decrease in the vesicular ergosterol flux and the increase of the
non-vesicular ergosterol moving through the fluxes v32,39 and v39,32
(see Fig. 1).
Total mass simulations
A total mass analysis was executed in order to validate the SL-E
model against literature experimental data in which the total
amount of sterols sub-populations and complex sphingolipids was
quantified under different experimental conditions [3,25,47].
Figure 1. Ergosterol model for yeast. Solid boxes represent time dependent variables, italics represent time independent variables, consecutive
arrows represent multiple enzymatic reactions taking place, and the dashed arrow indicates an inhibitory feedback signal. Blue boxes represent
metabolites in common with the sphingolipid pathway from Fig. 2. Abbreviations for the time dependent variables: Palmitoyl-CoA (Pal-CoA), X12;
Acetyl-CoA (Ac-CoA), X25; 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), X26; Mevalonate,X27; Farnesyl pyrophosphate (Farnesyl-PP), X28;
Squalene,X29; Lanosterol,X30; Zymosterol,X31; Endoplasmic reticulum ergosterol (Ergosterol), X32; Steryl Lanosterol, X33; Steryl Zymosterol, X34; Steryl
Ergosterol in Bulk Lipid Particles (Steryl Ergosterol-1), X35; Outer Leaflet Ergosterol in the Plasma Membrane (Ergosterol-o), X36; Detergent insoluble
plasma associated ergosterol (Ergosterol-r), X37; Internal Acetate (Acetate Int.), X38; Inner Leaflet Ergosterol in the Plasma Membrane (Ergosterol-i), X39;
Steryl Ergosterol in Plasma Membrane Associated Lipid Particles (Steryl Ergosterol-2), X40; Golgi Associated Complex Sphingolipids (CS-g), X8+X18+X19;
Plasma Membrane Associated Complex Sphingolipids (CS-m), X20+X21+X22.
doi:10.1371/journal.pone.0028344.g001
Ergosterol Pathway Mathematical Modeling in Yeast
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28344
Figure 2. Sphingolipid model for yeast. Solid boxes represent time dependent variables, italics represent variables assumed to be time
independent, dashed boxes represent variables with inhibitory or activating effects, dashed arrows represent more than one enzymatic reaction
taking place. Blue boxes represent metabolites in common with the ergosterol pathway from Fig. 1. Abbreviations for the time dependent variables:
3-Keto-Sphinganine (KDHS), X1; Sphinganine (DHS), X2; Dihydroceramide (Dihydro-C), X3; Sphinganine-1P (DHS-P), X4; 4-OH-Sphinganine (PHS), X5;
Ergosterol Pathway Mathematical Modeling in Yeast
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The simulation of the effects of a greatly reduced activity (1%) of
SPT; (X157) on the total mass in the SL-E model shows a 26% and
55% decrease in the CS-associated ergosterol (X37) after 60 min
and 120 min of the computational experiment, respectively
(Table 1).
When the 1% SPT condition is implemented in the SL-E model
(used for the dynamic simulations from Figs. 3, 4, and 5), there is a
20% and 44% decrease in the CS-associated ergosterol (X37) after
60 and 120 minutes, respectively (not shown). In the literature a
similar 23% decrease in the DIM associated ergosterol (see Table 1
in ref [25]) and a 53% decrease in the DIGs (see Fig. 4b in ref [3])
had been recorded at the restrictive temperature for the lcb1-100
relative to wild type cells after 60 and 120 minutes, respectively.
Table 1 ergosterol DIM associated (X37) reduction occurs in
spite of the reduced vesicular flux, which does not represent more
than 2% of the total ergosterol forward-backward flux (see Table S3
for flux values).
Simulations with 1% IPC synthase activity (Table 1) show
results similar to those obtained with 1% SPT. Both exhibit
decrease of the CS-associated ergosterol (X37) and increases in the
non-CS associated ergosterol sub-populations.
Ceramide synthase (X134) was decreased to 12.5% of its basal
value (Table 1), simulating a decrease in enzymatic activity that
was reported when 100 mM of Fumonisin B1 was added to the
medium (see Fig. 6A in ref [47]). The effects of this modification
on the ergosterol sub-populations were modest and changes in
Phytosphingosine-1P (PHS-P), X6; Phytoceramide (Phyto-C), X7; Inositol Phosphorylceramide (IPC-g), X8; CDP-Diacylglycerol (CDP-DAG), X9;
Phosphatidylserine (PS), X10; Phosphatidic Acid (PA), X11; Palmitoyl-CoA (Pal-CoA), X12; Serine, X13; sn-1,2-Diacylglycerol (DAG), X14; Phosphatidylinositol
(PI), X15; Inositol (I), X16; Cytidine Diphosphate-Ethanolamine (CDP-Eth), X17; Mannosylinositol Phosphorylceramide (MIPC-g), X18; Mannosyldiinositol
Phosphorylceramide (M(IP)2C-g), X19; Inositol Phosphorylceramide in Plasma Membrane (IPC-m), X20; Mannosylinositol Phosphorylceramide in Plasma
Membrane (MIPC-m), X21; Mannosyldinositol Phosphorylceramide in Plasma Membrane (M(IP)2C-m), X22; Very Long Chain Fatty Acid (C26-CoA), X23;
Malonyl-CoA (Mal-CoA), X24; Acetyl-CoA (Ac-CoA), X25; Endoplasmic reticulum ergosterol (Ergosterol), X32; Plasma Associated, Detergent Insoluble
ergosterol (Ergosterol-r), X37; Internal Acetate (Acetate Int.), X38.
doi:10.1371/journal.pone.0028344.g002
Figure 3. Experimental data vs. SL-E model simulation results for steryl-esters and total sterols. After an external pulse bolus (Panels A–
C). (A) Dynamics adapted from Taylor and Parks [42] after pulse-chase bolus of [14C]-Acetate. (B) Simulation for total steryl-esters (X33+X34+X35+X40)
and total sterols (X30+X31+X32+X36+X37+X39) after pulse bolus of labeled acetate. (C) Transported external label acetate (X125) and cytoplasmic acetate
(X38). The initial label of external acetate was 125 mM. After 30 min pulse-chase with external [
14C]-acetate (Panels D–F). (D) Dynamics adapted from
Taylor and Parks [42] after pulse-chase bolus of [14C]-Acetate. (E) Model simulation for steryl-esters (X33+X34+X35+X40) and total sterols
(X30+X31+X32+X36+X37+X39) after pulse-chase bolus of labeled acetate. (F) Transported external label acetate (X125) and cytoplasmic acetate (X38). The
initial label of external acetate was 125 mM. The % Total Sterols was calculated as percent with respect to the total sterol amount for the S. cerevisiae
wild type strain. In Fig. 3B and E, the ‘‘Normalized % Total Sterols’’ were normalized against the last experimental values for the steryl-esters from Figs.
A and D.
doi:10.1371/journal.pone.0028344.g003
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these pools of ergosterol did not go beyond 5%, thus,
demonstrating minimal effects.
With the exception of the ceramide synthase experiments,
which result in values within 5% of the basal values for any of the
tested conditions, the remaining non-CS associated ergosterol sub-
populations (free ergosterol) present a slight but consistent increase
under the reduced SPT and IPC synthase conditions (Table 1).
The first column from Table 2 shows a decrease of the total PM
ergosterol of 4 and 11% for the SPT condition at 60 and
120 minutes respectively. This decrease is also reflected in the
Figure 4. SL-E model results for an external pulse-chase bolus similar to the one in Fig. 3F. (A) Complex sphingolipids: Golgi
compartment plus plasma membrane IPC (X8+X20), Golgi compartment plus plasma membrane MIPC (X18+X21), Golgi compartment plus plasma
membrane M(IP)2C (X19+X22). (B) Ergosterol sub-populations: ergosterol in endoplasmic reticulum (X32), ergosterol steryl-ester-1 (X35), ergosterol
associated with the complex sphingolipids (X37), plasma membrane ergosterol in inner leaflet (X39), ergosterol steryl-ester-2 (X40).
doi:10.1371/journal.pone.0028344.g004
Figure 5. SL-E model results for an external pulse-chase bolus similar to the one in Fig. 3F. Pools: Steryl-esters (X33+X34+X35+X40), Sterol
(X30+X31+X32+X36+X37+X39). Ergosterol sub-populations: ergosterol in endoplasmic reticulum (X32), ergosterol steryl-ester 1 (X35), ergosterol
associated with the complex sphingolipids (X37), plasma membrane ergosterol in inner leaflet (X39), ergosterol steryl-ester 2 (X40). (A) Decrease to 1%
in IPC synthase activity (X133). Dynamic simulation for the steryl-esters pool and total sterols after pulse-chase bolus with labeled acetate. (B) Decrease
to 1% in IPC synthase activity (X133). (C) Decrease to a 1% in serine palmitoyl transferase activity (X157). Dynamics simulation for the steryl- esters pool
and total sterols after pulse-chase bolus with labeled acetate. (D) Decrease to a 1% in serine palmitoyl transferase activity (X157).
doi:10.1371/journal.pone.0028344.g005
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second and fourth columns for the total ergosterol sub-populations
and total sterols respectively.
The Table 2 reduction in total PM ergosterol, under the condition
of the decreased SPT, at 60 minutes, is smaller than reported for the
lcb-100 strain after 60 minutes at the restrictive temperature, using
immunoblotting Gas1p antibodies (see Fig. 5A in ref [25]). The
reason for this difference may be that the marker Gas1p is not
properly delivered to the plasma membrane in lcb1-100 cells [56].
Table 1. Steady-state total mass of ergosterol sub-populations in the SL-E model under different experimental conditions, after
60 min.
ER Erg. PM Outer Erg. DIM Erg. PM Inner Erg.
X32 X36 X37 X39
Wild Type (% total sterols) 9,51 4.75 42.80 47.55
1% SPT 1.09 1.20 0.74 1.13
1% SPT (120 min) 1.20 1.28 0.45 1.23
1% IPC synthase 1.05 1.19 0.72 1.11
12.5% Ceramide synthase 1.03 1.04 0.95 1.03
Wild type condition is represented with basal values; the other experimental conditions correspond to fold changes with respect to the wild type after decreasing the
specific activity of serine palmitoyl transferase (X157), IPC synthase (X133), and ceramide synthase (X134) to 1% or 12.5%.
doi:10.1371/journal.pone.0028344.t001
Figure 6. Yeast ergosterol diagram based on the highest sterol related SL-E logarithmic gains (metabolites) from Table S6. The
diagram summarizes the ten time dependent metabolites of the ergosterol pathway associated with the highest sum of logarithmic gain magnitudes
that are bigger than 1 (see Fig. 1 and Table S6). Solid boxes show time dependent variables and italics represent time independent variables.
Consecutive arrows represent multiple enzymatic reactions, and the dashed arrow indicates a feedback signal. Blue boxes represent metabolites that
also appear in the sphingolipid pathway (Fig. 2). Abbreviations for the time dependent variables: Acetyl-CoA (Ac-CoA), X25; Endoplasmic reticulum
ergosterol (Ergosterol), X32; Steryl Lanosterol, X33; Steryl Zymosterol, X34; Steryl Ergosterol in Bulk Lipid Particles (Steryl Ergosterol-1), X35; Outer Leaflet
Ergosterol in the Plasma Membrane (Ergosterol-o), X36; Detergent insoluble plasma associated ergosterol (Ergosterol-r), X37; Internal Acetate (Acetate
Int.), X38; Inner Leaflet Ergosterol in the Plasma Membrane (Ergosterol-i), X39; Steryl Ergosterol in Plasma Membrane Associated Lipid Particles (Steryl
Ergosterol-2), X40; Golgi Associated Complex Sphingolipids (CS-g), X8+X18+X19; Plasma Membrane Associated Complex Sphingolipids (CS-m),
X20+X21+X22.
doi:10.1371/journal.pone.0028344.g006
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With the exception of the condition with decreased SPT at
120 minutes for PM ergosterol, the rest of the metabolites in
Table 2 show small variations with respect to the wild type basal
values in the first row. Similar to the simulations, no significant
variations are reported experimentally when one compares the
total ergosterol and ergosterol-esters from wild type vs. lcb1-100
strains at permissive or restrictive temperatures (see Table 1 in ref
[25]).
In spite of the congruence between the SL-E model predictions
and experiments addressing total ergosterol and ergosterol-ester
[25], it must be cautioned that the SL-E model does not include
other organelles rich in sterols, such as endosomes, or vacuoles
that might contribute to the total ergosterol mass [57].
In general, a decrease in complex sphingolipids was observed
for all simulated conditions (Table 3). The complex sphingolipids
of the golgi and, in particular the IPC (X8) are the metabolites most
affected in all computationally tested conditions (not shown
individually). Table 3 decreases in complex sphingolipids are
expected because the simulations affect the enzymes of de novo
sphingolipid synthesis that are needed for the formation of
complex sphingolipids. The finding is indirectly consistent with
results of labeling the lip1 mutant (ceramide synthase) [58], and
even more with labeling after myriocin treatment [59], which
suggest a decrease in sphingolipid biosynthesis that is less evident
when one examines MIP2C rather than the IPC.
Table 3 most significant variation in complex sphingolipids is
observed for reduced SPT activity, which results in a 66% and
92% decrease in IPC synthase at 60 and 120 minutes respectively.
Overall, this condition reduces the complex sphingolipids levels by
46% and 68% at 60 and 120 minutes, respectively.
Table 3 shows similar reductions in complex sphingolipids
under 1% IPC and 1% SPT conditions. A decrease in ceramide
synthase activity leads to a much smaller decrease in the complex
sphingolipids after 60 min. The simulated effect of fumonisin B1 is
significantly smaller than reported in an experimental study (see
Fig. 7B in ref [47]); however, in this study the complex
sphingolipid levels were measured after longer fumonisin B1
application (6 generations).
Discussion
For the first time, the sphingolipid and the ergosterol
biosynthetic routes have been integrated into a single mathemat-
ical model.
Model validation was accomplished by comparing the dynamics
of sterols and sterol esters with published time courses. Under
different conditions and strains, the sphingolipid-ergosterol model
(SL-E) was able to simulate the experimental levels of specific
ergosterol sub-populations obtained with the lcb1-100 strain, a
temperature conditional mutant for the SPT, the first enzyme of
the sphingolipid route.
The validated SL-E model was used to predict the metabolomic
dynamics of the sphingolipid-ergosterol pathways after drug
treatment. Specifically, we simulated the effect of drugs affecting
sphingolipid and sterol enzymes and studied subsequent changes
in sterols and sterol esters sub-populations.
Table 2. Steady-state values of PM ergosterol, total ergosterol, total ergosterol-esters, total sterols, and total steryl-esters in the SL-
E model under different experimental conditions, after 60 minutes.
PM Ergosterol Total Ergosterol Total Erg. Esters Total Sterols Total Steryl Esters
X36,X37, X39 X32, X36, X37, X39 X35, X40 X30, X31, X32, X36, X37, X39 X33, X34, X35, X40
Wild Type (% total sterols) 95.1 104.61 45.7 112.91 62.2
1% SPT 0.96 0.97 1.05 0.98 1.05
1% SPT (120 min) 0.89 0.92 1.11 0.94 1.12
1% IPC synthase 0.94 0.95 1.02 0.95 1.01
12.5% Ceramide synthase 1.00 1.00 1.01 1.00 1.01
Wild type condition is represented by the sum of the basal values; the other experimental conditions correspond to fold changes with respect to the wild type after
decreasing the specific activity of serine palmitoyl transferase (X157), IPC synthase (X133), and ceramide synthase (X134) to 1% or 12.5%.
doi:10.1371/journal.pone.0028344.t002
Table 3. Steady-state total mass of complex sphingolipid sub-populations in SL-E model under different experimental conditions,
after 60 minutes.
IPC MIPC M(IP)2C CS
X8, X20 X18, X21 X19, X22 X8, X18, X19, X20, X21, X22
Wild Type (mol%) 1.02 1.40 0.085 2.505
1% SPT 0.34 0.68 0.57 0.54
1% SPT (120 min) 0.08 0.49 0.54 0.32
1% IPC synthase 0.35 0.66 0.63 0.53
12.5% Ceramide synthase 0.83 0.92 0.94 0.89
Wild type condition is represented by the sum of the basal values; the other experimental conditions correspond to fold changes with respect to the wild type after
decreasing the specific activity of serine palmitoyl transferase (X157), IPC synthase (X133), and ceramide synthase (X134) to 1% or 12.5%. Complex sphingolipids: IPC in
Golgi compartment plus plasma membrane (X8+X20), MIPC in Golgi compartment plus plasma membrane (X18+X21), M(IP)2C in Golgi compartment plus plasma
membrane (X19+X22). CS represents the total of complex sphingolipids.
doi:10.1371/journal.pone.0028344.t003
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Sensitivity analysis indicates that the SL-E model is robust,
showing generally low sensitivities for the parameters with respect
to concentrations and fluxes (see Tables S5, S6, S7, S8, and S9).
The higher sensitivities are mostly associated with metabolites that
are also involved in other pathways, which are not modeled here, a
phenomenon that was similarly observed in the sphingolipid
system [38].
Fig. 6 presents the mechanisms involved in the ER-plasma
membrane ergosterol transport with the highest log-gain sensitiv-
ities, including thiolase/synthase (X171). Because the thiolase/
synthase is a common enzyme shared with mammalian cells, only
the mechanisms associated with ergosterol transport are interesting
as antifungal drug targets. These ergosterol processes are in fact
the target of polyenes antifungals such as Nystatin and
Amphotericin B [35]. The SL-E model was subjected to gross
and fine tuning validations. First, it was tested against measure-
ments of the dynamics of total sterol and steryl-esters [42], and
indeed the simulated dynamic trends were qualitatively consistent
with experimental data describing the dynamics of de novo synthesis
of sterols and steryl-esters after perturbations with external
radioactive acetate (Fig. 3). Second, with more refined data under
different experimental conditions and strains [3,25], the SL-E
model was able to simulate correctly the levels of specific ergosterol
sub-populations mimicking the experimental results obtained in
the lcb1-100 strain (which shows near total loss of SPT activity at
restrictive temperatures) by decreasing the SPT (X157) to 1% their
basal value. This suggests that the vesicular co-transport of
ergosterol and CS is principally responsible for the decrease in CS-
associated ergosterol (X37). Interestingly, a similar 34% decrease
for the newly synthesized cholesterol in rafts was reported in
mammalian kidney cells when the vesicular transport from the
Golgi compartment to the cell surface was impaired by decreasing
the incubation temperature from 37uC to 15uC [60].
Also, both the lcb1-100 mutant strain [25] and the SL-E model
showed a 50% decrease in complex sphingolipids (CS) with respect
to the wild type strain after 60 minutes (Table 3). At first glance,
this CS decrease may suggest a proportional 50% reduction in the
DIM-associated ergosterol. However, this is not supported by
experimental results as reported by the Bauman group [25] nor by
the simulation results with the SL-E model. Instead, both show a
decrease of around 30% in CS-associated ergosterol (X37) (Table 1).
This result highlights the importance of the biosynthetic pathways
as complex systems that are able to affect the PM ergosterol levels.
Given that the experimental observations were not used for model
construction or parameterization, the favorable comparisons
between data and simulation results thus provide a significant
measure of validation.
As shown in Fig. 1, the SL-E model does not include the PM’s
inner microdomains. This raises the question of whether the
percent reductions for the lcb1-100 DIM-associated ergosterol [25]
and the 1% SPT CS-associated ergosterol (X37) (Table 1) are both
similar, since the inner microdomain ergosterol can probably
contribute to the DIM-associated ergosterol. As noted in the
introduction, the ergosterol-phospholipid interactions of the
plasma membrane’s inner microdomains depend principally on
the degree of fatty acid saturation of the phospholipids. Devaux
and Morris comment that the spatial-temporal coexistence of the
rafts at both sides of the membranes probably depends on the
transmembrane proteins and/or the degree of membrane
curvature [61]. We suggest here that their co-localization probably
also requires the interdigitations of the inner lipids with the very
long CS fatty acid chains tails for their formation and stabilization
[26]. However, until we gain further knowledge, it is not known if
these forces are strong enough to be maintained during DIM
purification. Another likely reason for the similarity between the
simulations and the experimental results for the CS-associated
ergosterol after decreasing the SPT activity is that the proportion
for the inner/outer plasma membrane ergosterol microdomains is
not affected in the lcb1-100 mutants and/or by the different
experimental conditions reported by Baumann and coworkers
[25]. More experimental evidence is necessary to clarify which
ergosterol sub-population(s) are extracted within the DIM pool.
It is also important to remember that the comparison of
simulated SPT inhibition (Figs. 5C–5D) with lcb1-100 results [25]
needs to be considered with caution. The lcb1-100 strain exhibits
lower complex sphingolipid levels even at a permissive tempera-
ture [25], and has a greater sensitivity to stress [62–64].
As a whole, from the predictions from Fig. 5 and Tables 1, 2
and 3, we can conclude that a decrease in the CS plasma
membrane levels will concomitantly produce: a) a reduction in the
plasma membrane CS-ergosterol level, b) a moderate increase of
the free ergosterol sub-populations, and c) slightly longer sterol
recovery times after [14C]-acetate perturbations. The steryl-ester
dynamics are affected only when the specific activity of SPT was
decreased.
Predictions in Table 2 showed that the levels of the sterols and
steryl-esters are not significantly modified when key enzymes of the
sphingolipid pathway are affected. This homeostatic phenomenon
has been observed in yeast [36] and mammalian cells [65], which
by diverse strategies are able to maintain the sterol and steryl-ester
sub-populations within an optimum range. With the exception of
1% SPT at 120 minutes, Table 2 indicates that the sterols and
steryl esters pools are inside a few percent (6%) of their respective
basal values in spite of some aggressive in silico conditions tested,
such as in the lcb1-100 temperature conditional mutant.
The SL-E model is able to reproduce the very efficient
homeostatic sterol balance in yeast that has been observed under
different experimental conditions (e.g. [25]). The SL-E model
homeostasis encompasses the ergosterol biosynthesis precursors,
end product feedback regulation, sub-cellular sterol compartmen-
talization, the plasma membrane ergosterol flip-flop, and the back
and forth movement of microdomain ergosterol in the plasma
membrane. The model also includes sub-populations of lipid
particles as important depositories of esterified sterols. Finally, the
ergosterol portion of the model shares precursor metabolites and
co-transport processes with the sphingolipid-glycerolipid pathway.
The SL-E simulation of labeled acetate pulse chase (Fig. 3D)
does not entirely match the results of [14C]-acetate chase
experiments for the sterol and steryl-ester pools, especially for
the steryl-esters (Fig. 3E). These differences between experimen-
tation and simulations can be caused by diverse factors inside and/
or outside the modeling framework. Within the modeling
construction, two main factors could affect the dynamics of sterols
and steryl-esters. The first is that Taylor and Parks’ pulse chase
[14C]-acetate experiments included labeled contributions from not
modeled organelles that may contain sterols, such as the
mitochondria, endosomes, the nucleus, and the vacuoles [33,57].
The other probable reason is that the model does not include the
long list of all sterols [29,66] and steryl-esters [40,41,67] that are
present along the ergosterol biosynthetic route in yeast.
Outside the modeling framework, four main causes could
contribute to the observed difference between the experiments and
simulations. The first relates to the CPM correction factor of 27/
43 employed in the experiments of Taylor and Parks (calculated
with 16 palmitoyl-CoA and 27 sterol carbons) [42], which does not
totally subtract the CPM contribution of the fatty-acids from the
steryl-esters because the steryl-ester synthase (X181, X183) can
catalyze the incorporation of fatty-acyl chains of different lengths
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[68]. The second factor is the assumption that the steryl-ester fatty
acids and the sterols have the same specific activity which, as
Taylor and Parks state, is not necessarily true, especially when
pulse-chase experiments are conducted (Fig. 3D). A third factor,
that possibly affected Taylor and Parks’ dynamic pulse-chase
experiments (Fig. 3D), was the procedure of washing the cells with
unlabeled medium to remove the [U-14C] potassium acetate after
30 minutes of labeling. This process raises the possibility that the
chase contributes to the sharp decrease in the radioactivity
incorporation rates observed at the third and fourth time points for
the sterols and steryl-esters [42]. Fourth, the time points of
initiating the [14C]acetate pulse and the pulse-chase experiments in
the studies of Taylor and Parks are not clear, and the first
documented time points correspond to 250 minutes (Fig. 3A) and
566 minutes (Fig. 3D) (see Figs. 1C and 2B in ref [42]). Paralleling
the time course used by Taylor and Parks (see Figs. 1B and 2A in
ref [42]), the SL-E simulations reflect initiation of treatment in the
middle of the exponential growth phase (Figs. 3B, 3E, 4, 5, and
Fig. S2).
During the development and implementation of the SL-E
model, two aspects of the sterol and steryl-esters biology were
highlighted. First, in spite of the fact that the esterified pools and
associated enzymes are not essential for yeast viability [69,70],
these studies show that the dynamics of sterols and steryl-esters
depends profoundly on the lipid particles (LP) organelles. Second,
the importance of clarifying the relationship between the LP sub-
pool-2 (X40) and the Plasma Membrane Associated structures
described by the Daum group was realized [71], since these two
lipidic structures are both rich in sterol enzymes (as the Erg1p and
the Erg6p) [32,72] and both are in close association with the PM
[69].
The scope of the SL-E model is quite broad. Foremost, it can
complement experimental research as a tool aiding our under-
standing of yeast lipidomics under different conditions. For
instance, the comprehensive sensitivity analysis of the model (see
Tables S5, S6, S7, S8, and S9 for details) facilitates the identification
of processes that influence the pathway more than others. Tables
S5, S6, S7, S8, and S9 shows that there are three principal groups of
sterol related metabolites with different degrees of sensitivity,
namely the sterol precursors, the ergosterol sub-populations, and
the steryl-ester sub-populations, of which the last group exhibits
the highest sensitivities. These three blocks of sterol-related
metabolites are expected to be more influenced by perturbations
from the rest of the SL-E model.
The model is also a valuable tool for testing hypotheses
regarding the dynamics of sterols and their acylated forms after
specific changes in sphingolipid and/or sterol associated enzymes
from the SL-E model (e.g., Table S10). An example of this type of
analysis was recently executed with the sphingolipid pathway
alone [38]. Finally, the proposed model could serve as the basis for
a global SL-E model, which could support predictions of changes
in lipid levels under untested conditions. An analysis of this type
with a sphingolipid model helped with the interpretation of
microarray data characterizing the diauxic shift [73].
As pathway models become more comprehensive, it will
become increasingly difficult to keep track of all details and to
test, diagnose, and validate them. This difficulty may be addressed
in different ways, for instance, by focusing on the modularity of
biological systems, complexity reduction per time scale separation,
or by designing tools for the creation, analysis, and sharing of
models that are based on biologically motivated rules [74]. These
strategies should also include techniques for the nontrivial
representation of polymerization processes in pathway systems
where chemical species are attached to or removed from larger
polymeric molecules, such as complex carbohydrates, fatty acids,
ribonucleic acids or membranes. Such techniques will be especially
relevant for processes such as the ones described here, where the
dynamics of fatty acids and their interactions with lipid
membranes are critical.
Methods
Considerations for Model Construction
General Assumptions. We know that sterol biosynthesis is
localized in the ER [29] and that both the sterol and the
sphingolipid pathways share acetyl-CoA as a building block for
fatty acyl and mevalonate formation, respectively (Figs. 1 and 2).
The SL-E model considers palmitoyl-CoA as the only initial
substrate (Fig. 1) and does not account for different acyl chain
lengths.
Ultimately both pathways probably converge to form cargo
vesicles and plasma membrane microdomains composed of
ergosterol and complex sphingolipids [75] (Figs. 1 and 2).
Under aerobic exponential growth, the metabolites involved in
the heme-independent section are present at very low levels, which
is assumed to be a consequence of an efficient conversion into
sterols by the heme-dependent enzymatic reactions downstream
[76]. A consequence of the low concentration is a paucity of
literature information about metabolites preceding lanosterol. To
circumvent this issue, the presence of heme-independent metab-
olites is often experimentally characterized with strains containing
specific gene deletions or with the inhibition of enzymatic activity
by means of drugs and toxins [20], but it is uncertain to what
degree the results from such experiments are representative for the
wild type strain. Because of the lack of sufficient and relevant
information, the heme-independent section of the model was
limited to metabolites reported under aerobic conditions (Fig. 1).
In the downstream heme-dependent section, we specifically
included the enzymes Erg1p, Erg11p, and Erg6p. The reasons for
this inclusion are the following: First, gene over-expression studies of
Veen and collaborators suggest that Erg1p and Erg11p are the major
regulatory steps for the ergosterol biosynthetic route [77]. Second,
Erg11p is the crucial juncture for functional sterol molecules,
because enzymatic disruptions at or before this point result in
cessation of sterol prototrophy, while gene knockout mutants
between Erg6p and the end of the route are viable even if significant
changes are observed in the membranes of these strains [29,36,78].
It became evident during the modeling process that it would be
beneficial to subdivide the total ergosterol pool into sub-pools
corresponding to free ergosterol and ergosterol associated with
detergent-insoluble membranes (DIM), which could have different
properties and functions (e.g., [25]). The DIM pool is considered as
a single pool, although in reality it is likely a conglomerate of
individual plasma membrane microdomains [54].
Preliminary model analysis implied the need to include the end
product feedback regulation of ergosterol. Furthermore, it is
reported that ergosterol promotes transcriptional feedback regu-
lation upon ERG10, the gene coding for acetoacetyl-CoA thiolase
[79]. Other feedback regulation, such as the translational
repression of mevalonate HMG-CoA reductase by its product
mevalonate [80] or external allosteric ergosterol inhibition [81],
were not included because these regulatory mechanisms are only
active under conditions that are different from those addressed by
the model. The effect of genetic regulation by mevalonate on the
HMG-CoA reductase isoenzymes HMG1 and HMG2 occurs
during anaerobic growth and in cells moving from log-growth to
stationary phase. Specifically, HMG1 is preferentially expressed
during logarithmic aerobic growth, and HMG2 is translated during
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the stationary phase and/or under anaerobic growth [80].
Allosteric inhibition of Erg10p by ergosterol is exerted by external
ergosterol [81], but only under anaerobic conditions. When
oxygen is available in the medium, S. cerevisiae preferentially
synthesizes its own ergosterol even in the presence of external
sterols [82].
The sphingolipid component of the SL-E model includes the de
novo and salvage production of ceramides, as well as the formation
and transport of complex sphingolipids between the Golgi and the
plasma membrane. It also includes glycerolipids directly related
with the sphingolipid pathway and the formation of CS from
phytoceramide (X7) and dihydroceramide (X3), with phosphatidy-
linositol (PI; X15) as a cosubstrate, through the inositol phosphor-
ylceramide synthase (X133) reactions (Fig. 2). Predictions with the
sphingolipid model pointed toward the importance of PI for the
dynamics of the complex sphingolipids, and this finding was
confirmed experimentally by thin layer chromatography (TLC)
time course data after pulse labeling with inositol [38]. Moreover,
the sphingolipid model properly simulated the dynamics of long
chain base phosphates LCB-P’s (X4, X6) for the wild type and the
sphingosine-phosphate lyase (X150) knockout [38].
Vesicular and non-vesicular ergosterol transport. Due
to the lack of specific data for the proteins associated with the
vesicular transport, the SL-E model does not include a specific
protein (for example Sec1p, Sec14p, or Sec23p) involved in the
transport of ergosterol and CS from vesicular ER to PM through
the fluxes v32,37 and v37,32 [83,84]. Instead, we described these
transport processes with simple first-order mass action reactions,
which had previously been shown to represent the kinetics of these
mechanisms quite well [38].
The non-vesicular lipid transport is associated with transfer and
transport proteins (generically called transferases and flippases), which
facilitate the movement of lipids between membranes and the
trans-bilayer forward-backward ER-PM ergosterol flip-flop. These
flippases play an important role in maintaining ergosterol
homeostasis at both sides of the membrane (e.g., [85]).
Because the lack of detailed kinetic information for the proteins
associated with the non-vesicular lipid transport [84,86] mass
action formulations have been used in the literature for their
description showing good agreement with experimental data
[87,88]. In the SL-E model, the mass action representation of non-
vesicular transport also seemed appropriate, as judged by
comparisons with experiments characterizing the sterol dynamics
with de novo external [14C]-acetate perturbations [42] and wild type
vs. lcb1-100 strain experiments measuring the mass of ergosterol in
the plasma membrane [3,25] (see result section).
The SL-E model does not include a trans-bilayer inner-outer
leaflet flip-flop movement for the ergosterol DIM lipid-ordered pool
(X37) because it seems that the contribution of this ergosterol pool is
low due to its strong association with complex sphingolipids [87].
Assumptions regarding ergosterol and complex
sphingolipids in raft formation. It is known that enzymatic
reactions taking place in crowded lipid solutions behave differently
than reactions occurring in water soluble media [89,90]. Lipid-
embedded enzymes can catalyze lipid translocations and
microdomain association and dissociation [85,86,91], possibly
leading to fractal kinetics, which is well described with power-law
formulations that are at the core of BST [92–94]. We used such
fractal kinetic representation for flux v36,37, which represents the
efflux of the free outer leaflet ergosterol and their association with
the complex sphingolipids from the plasma membrane.
No specific references were found about the possible localization
of complex sphingolipids outside microdomains, but it has been
reported that the bulk of ceramide is localized in ordered lipid
domains with a small concentration of ceramide not associated
with rafts [95]. The SL-E model initially assumes that complex
sphingolipids of the PM are present in the compartment associated
with the ergosterol in DIMs (X37) (see Fig. 1).
In addition to ergosterol, the inner leaflet of the yeast plasma
membrane contains other abundant lipids, such as the anionic
phosphatidylinositol (PI) and phosphatidylserine (PS) and the
neutral phosphatidylethanolamine (PE) [96,97].
To summarize these findings and assumptions, the current SL-E
model represents a number of processes at the membrane, but
does not account for specific structures at the inner leaflet of PM or
for transmembrane proteins that could contribute to the formation
of inner leaflet microdomains.
Lipid particles (LP). No direct experimental evidence is
available in the literature of how Yeh2p gets access to its substrate
or if the sterol products of the Yeh2p reaction are used for PM
biogenesis [69]. Thus, the SL-E model assumes that the entire flux
going through Yeh2p (X182) contributes to the ergosterol pool (X39)
at the PM inner leaflet (Fig. 1).
Total mass experiments. For the total mass simulations
(Tables 1, 2, and 3), the SL-E model was balanced for the plasma
membrane and for bidirectional lipid particle fluxes, which are
assumed to be in equilibrium when the cells are no longer growing.
This balancing is not entirely trivial, because the contributing
compartments have different volumes, which complicate
concentration and flux estimations (see Table S3 for details).
Moreover, because the yeast population at steady-state contains
the same numbers of cells growing and decaying, and because
yeast cell size [98] and organelles such as the vacuole [99] increase
in size during aging, it was assumed that the steady-state fluxes
associated with the ER, PM, and LP balance to zero. Finally, in
the theorical treatment proposed by Baumann et al the transport
of free sterols between the ER and PM, and between the pools of
free and raft sterols are assumed both in equilibrium [25].
Specifically, the vesicular co-transport of ergosterol and CS and
the fluxes of lipid particles were balanced. The flux v40,39, which is
catalyzed by the plasma membrane hydrolase Yep2p (X182), was
set to zero because Yep1p is the sole active steryl-ester hydrolase
under heme-deficient conditions, while Yeh2p and Tgl1p are
inactivated [100].
Mathematical Methods
Modeling Framework and Equations. There are no a priori
guidelines for setting up mathematical models of complex systems.
In this situation, Biochemical System Theory (BST) [44,46] has
proven to be a very useful first default approach, especially if
quantitative information is scarce. Generically, the dynamic of a
metabolic pathway is modeled as a system of ordinary differential
equations, namely
d~X
dt
~N~V ð1Þ
Where ~X is the vector of metabolites, dXi=dt is the vector of
derivates, N is the stoichiometric matrix, and +is the vector
containing the fluxes ni in the metabolic system. In BST, these
fluxes are represented as power-law functions of the form
vi~ci P
nzm
j~1
X
fi,j
j ð2Þ
Each term contains exclusively those variables that have a direct
effect on this flux. Each variable is raised to a powerfkij , called a
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kinetic order, that quantifies the strength and direction of the
effect, and the product of variables is multiplied with a rate
constant cik that quantifies the turn-over rate of the process
[46,101,102].
Thus, each BST equation in the generalized mass action (GMA)
format reads
dXi
dt
~+ci1 P
nzm
j~1
X
f1ij
j +ci2 P
nzm
j~1
X
f2ij
j +:::+cik P
nzm
j~1
X
fkij
j ð3Þ
(e.g., [38,39,46,102]). There are n equations, one for each dependent
metabolite variable, and the products may also include up to m
further independent variables whose concentrations remain constant
over time. Typical examples are constant substrates and enzyme
activities.
It is straightforward to design a GMA model from a metabolic
diagram. In fact, this step can be accomplished with computer
software [103]. Each metabolite of interest, Xi (i=1,…n), is
represented by a differential equation that contains the difference
between all influxes and effluxes, and these are formulated as
specific power-law functions, as discussed above.
We therefore used our earlier GMA model of the sphingolipid-
glycerolipid system [38,39] and expand it to include the ergosterol
pathway with the same methods (see Materials S1 for details).
For stability and sensitivity analysis we linearized this system in
a logarithmic coordinate system (cf. [43,46]).
In order to compare our simulation results with data on sterol
and steryl-ester dynamics reported in the literature [42], labeled
and unlabeled metabolites were distinguished as separate variables
within the same system. Methods for this type of dynamic labeling
analysis were presented elsewhere [104,105]. This approach to
tracking labeled molecules through metabolic pathways was
illustrated with the sphingolipid pathway in yeast [38] and the
pentose pathway in Zymomonas mobilis [105]. Specific details are
found in Materials S1.
Treatment of Sterol Sub-Pools. The ergosterol pool was
subdivided into four sub-populations: ergosterol in the ER (X32),
ergosterol associated with the inner and outer plasma membrane
(PM) not in microdomains (X36, X39), and the CS associated
ergosterol pool (X37). In S. cerevisiae, the highest ergosterol
concentration is found in the PM [32,33]. To assure consistency
between the ergosterol pools in ER and PM, the ER ergosterol
concentration was calculated from a known relationship between
the two [25,32] (see Tables S1 and S2 for details). One ER
ergosterol sub-pool is in close contact with the PM and associated
with the PAM (PM associated membrane) structures described by
Pichler and collaborators [71]. However, this PAM ergosterol
concentration is similar to that estimated for ER bulk ergosterol,
and is composed of the same ergosterol that is not associated with
detergent-insoluble sphingolipid enriched complexes (DIGs) [3],
which suggested a representation of ER ergosterol as a single time
dependent variable (X32).
With no data available for the sterol plasma membrane trans-
bilayer distribution in yeast [61,106], we assigned equal ergosterol
concentrations to both sides of the lipid bilayer. The reasons for
this equal distribution are two: First, in spite of the asymmetric
phospholipid distribution in the plasma membrane [96], it is
known that the anionic glycerophospholipids (PI and PS) and the
neutral or zwitterionic phospholipids (PC, PE, PC) can accom-
modate sterols equally well [106,107]. This broad lipid affinity of
the sterols is mainly caused by their affinity according with the
degree of saturation of the fatty acyl chains, but the information
about the asymmetry of saturated acyl chains in the literature is
scarce. To a minor degree, the small polar head of the sterol can
also contribute to the non-covalent sterol interactions, which occur
mainly with the more homogeneous phosphatides and the
hydrophobic fatty acid chains of the lipids, and to a lesser degree
with the highly variable hydrophilic head groups. Second, the
rapid flip-flop of ergosterol reported for different preparations and
conditions [25,86] contributes to the fast equilibration of free
ergosterol.
It has been postulated that the inner plasma membrane
ergosterol forms rafts with surrounding phospholipids and
proteins, but their stability, degree of symmetric coexistence with
the outer microdomains, and the extent of the forces that produce
and maintain their existence, are not well understood
[61,106,108]. As highlighted by Silvius’ group [95] and others
[26], the inner microdomains may be formed by other
contributing factors outside the inner monolayer, such as the
trans-bilayer penetration of very-long acyl chains [26], and
transmembrane proteins associated with rafts [109]. Therefore,
it was decided not to include microdomains at the cytoplasmic side
of the plasma membrane in the SL-E model.
Finally, Baumann and collaborators established a 9:1 relation-
ship between free sterol and ergosterol associated with DIMs [25].
This relationship was used in the SL-E model for ergosterol on the
outer side of the plasma membrane (PM), which is associated with
CS (X37), thus leaving a smaller proportion of non-complex
sphingolipid associated ergosterol (X36) at this side of the PM.
Treatment of Steryl-Ester Sub-Pools. The steryl-esters are
confined to structures known as lipid particles (LP), which are
composed principally of triacylglycerols, sterol-esters, and
moderate quantities of triacylglycerol and ergosterol biosynthetic
enzymes [67,69,110].
Similar to the treatment of the different ergosterol sub-
populations, and assuring the correct relative concentrations
between the different organelles, the steryl-esters levels where
calculated from an observed linear relationship between the
endoplasmic reticulum sterols [32] and the steryl-esters in LPs [40]
(see Tables S1, and S2 for details).
The ergosterol ester in LP was split into two sub-populations
(X35 and X40) in a ratio of 10:1, with the smaller pool (X40) in direct
contact with the PM. The existence of LP sub-populations had
been reported by different laboratories and by different approach-
es. First, Daum and collaborators observed two sub-populations of
differently sized LPs [110]. Second, electron micrographs and
indirect immunofluorescence microscopy showed that not all LP
populations are PM associated [72,111]. Third, Leber and
collaborators proposed the possible existence of LP sub-popula-
tions in order to explain the differential Erg1p association with LP
subsets [72]. Fourth, the LP ergosterol sub-pool (X40) is a
consequence of the high STE hydrolase steryl ester activity
(X182) detected in the PM [33,110,112,113]. Finally, the
observation that Yeh2p in yeh1D/tgl1D double mutant strains
does not efficiently mobilize steryl-esters in vivo is consistent with
limited access of Yeh2p to the full intracellular LP steryl-ester pool,
as is predicted from the localization and topology of Yeh2p [112].
Very interestingly, the subdivision of steryl esters into sub-
populations turned out to be necessary in our model to assure
stability.
Representation of Fluxes. During exponential growth, the
fluxes of complex sphingolipids in and out of the plasma
membrane are not in steady state and move preferentially into
the plasma membrane [38]. This dominant flux direction is also
true for ergosterol, which moves back and forth in cargo vesicles
together with the complex sphingolipids, a transport process that is
indirectly modulated by Arv1p [2,114] and mediated by vesicle
associated proteins from the SEC family [83,84].
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The major ergosterol flux moves material from the ER to other
membranes through close contact of large sections of the ER with
the plasma membrane and with other organelles such as the
plasma membrane and the mitochondria [71,84]. For our
modeling purposes, the total bidirectional flux of ER ergosterol
toward the plasma membrane was estimated from experimental
data of Sullivan and collaborators [115]. The total bidirectional
flux of non-vesicular ergosterol from the ER to PM was subtracted
from the vesicular flux, and the ergosterol ester hydrolysis flux
through Yeh2p (see Fig. 1 and Table S3 for details).
Fluxes, such as the bidirectional flux between ER and LP, were
estimated from the assumption of a classicMichaelis-Menten process.
The calculated fluxes between ER and PM indicate a net flux toward
the steryl-ester formation, which is consistent with data addressing the
exponential growth phase [41,42,82,116]. Furthermore, two fluxes
divert ergosterol from the biosynthetic route to other organelles that
are not part of the model. The first one uses farnesyl diphosphate
(X28) through the farnesyltransferase (X179) reaction to the formation
of multiple isoprenoid metabolites, while the second flux channels
ergosterol from the ER to the mitochondria and other organelles
(X186). The latter flux is assumed to occur through direct ergosterol
translocation, because reports [71,84] show that multiple ER sections
are in close contact with the mitochondria and other organelles. The
remaining fluxes of the biosynthetic ergosterol pathway were
computed from the stoichiometry of the system and the fluxes
described before (see Table S3 for details).
Acetate Influx. In the presence of glucose, S. cerevisiae
represses expression of acetyl energy dependent transporters
[117,118]; under these conditions, the uptake of acetate is
proportional to the external acetate concentration [119,120].
The acetate uptake rate and the percent of incorporated,
undissociated acetate were based on literature data [42,121]. For
baker’s yeast growing in minimal medium supplemented with
yeast extracts, the external pH ranges between 4.5 and 5 [119] and
was reported to decrease steadily over the lifetime of the culture
[119,122], (Matmati, Nabil. 2010, personal communication). For
our simulations with labeled acetate, we assumed a medium pH
range between 4 and 4.5 and a proportion of 93% undissociated
acetate (which is consistent with the pKa of acetate). Thus, the
uptake rate constant of undissociated acetate was set to 0.0022
[121] (see Fig. S1 for details).
Model Diagnostics. Based on previously published models
for the sphingolipid-glycerolipid pathway [38,39,73,102], one
should expect the SL-E model to be stable and only moderately
sensitive. We tested and confirmed stability with standard methods
of eigenvalue analysis, which yielded exclusively negative real parts
(see Table S4 for details). The presence of some non-zero imaginary
eigenvalues permits oscillations in response to specific
perturbations to the system; some of these oscillations were
observed in the dynamics of some simulation results (e.g., Figs. 3, 4,
and 5, S2). Global model robustness is generally evidenced by low
sensitivities for the majority of parameters with respect to
metabolites and fluxes (see Table S5 for details). The high
percentage of sensitivities smaller than one in magnitude
indicates that the vast majority of perturbations in parameters
are attenuated by the model.
Supporting Information
Figure S1 Experimentally observed exponential decay
trend line for external radioactive acetate. Experimental
points (triangles) data adapted from Wang et al. (see Fig. 2 in ref
[121]). For all simulations presented in this manuscript, 100% of
the acetate in the medium (X125) was replaced with radioactive
acetate (L125).
(TIF)
Figure S2 SL-E model dynamics after external radioac-
tive acetate pulse bolus perturbation. Perturbation similar
to the one in Fig. 3C. Pools: Steryl-esters (X33+X34+X35+X40),
Sterol (X30+X31+X32+X36+X37+X39). Ergosterol sub-populations:
ergosterol in endoplasmic reticulum (X32), ergosterol steryl-ester-1
(X35), plasma membrane ergosterol in outer leaflet (X36), ergosterol
associated with the complex sphingolipids (X37), plasma membrane
ergosterol in inner leaflet (X39), ergosterol steryl-ester-2 (X40). (A)
Wild-type condition. Dynamic simulation for steryl-esters pool and
total sterols after pulse-chase bolus with labeled acetate. (B) Wild-
type ergosterol and steryl-ester sub-populations. (C) Decrease to
1% in IPC synthase activity (X133). Dynamic simulation for the
steryl-esters pool and total sterols after pulse-chase bolus with
labeled acetate. (D) Decrease to 1% in IPC synthase activity (X133).
Ergosterol and steryl-ester sub-populations. (E) Decrease to 1% in
serine palmitoyl transferase activity (X157). Dynamic simulation for
steryl-ester pool and total sterols after pulse-chase bolus with
labeled acetate. (F) Decrease to 1% in serine palmitoyl transferase
activity (X157). Ergosterol and steryl-ester sub-populations. (P)
Pulse-chase bolus with labeled external acetate. Transported
labeled acetate (X125) and cytoplasmic acetate (X38).
(TIF)
Table S1 Condensed literature information for the SL-E
metabolites. Included time dependent metabolites and
time independent non-enzymatic parameters.
(PDF)
Table S2 Condensed literature information for the SL-E
enzymes.
(PDF)
Table S3 Incoming and outgoing fluxes at model nodes.
(PDF)
Table S4 Eigenvalues for the flux balanced SL-E S-
system model.
(PDF)
Table S5 Global sensitivity statistics for the SL-E
model.
(PDF)
Table S6 SL-E logarithmic gains (of metabolites) with
magnitudes greater than one. First row and column
correspond to dependent and time independent variables,
respectively. The key for the variable names are given in Tables
S1 and S2. Rows not presented have only values smaller than one.
(PDF)
Table S7 SL-E rate constant sensitivities (of metabo-
lites) with magnitudes greater than one. First row and
column correspond to dependent variables and rate constants
respectively. The key for the variable names is given in Tables
S1and S2. Rows not present have only values smaller than one.
(PDF)
Table S8 SL-E logarithmic gains (of fluxes) with mag-
nitudes greater than one. First row and column correspond to
the fluxes and the independent variables respectively. The key for
the variable names is given in Tables S1 and S2. Rows not presented
have only values smaller than one.
(PDF)
Table S9 SL-E rate constant sensitivities (of fluxes) with
magnitudes greater than one. First row and column
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correspond to dependent variables and rate constants, respectively.
The key for the variable names is given in Tables S1 and S2. Rows
not presented have only values smaller than one.
(PDF)
Table S10 Simulation of the effect of statins in the SL-E
model. The total mass of ergosterol (Erg.) and complex
sphingolipid (CS) sub-populations in the flux balanced SL-E
model is presented under different experimental conditions, after
120 minutes. Wild type condition is represented by the basal
values; the two experimental conditions correspond to: A) fold
changes with respect to their corresponding basal values after
decreasing the specific activity of Thiolase/Synthase and HMG
Reductase to 10%, 1%, and 0.01%. B) Same conditions as in A but
with an simultaneous decrease to 1% the activity of IPC Synthase
(X133). Complex sphingolipids: IPC, MIPC, and M(IP)2C in Golgi
compartment (Golgi CS), or plasma membrane (PM). Last row
correspond at the result of divide the DIM ergosterol, and the PM
CS’s.
(PDF)
Table S11 Variables equivalence from Plas [48] into
MatlabH [49].
(PDF)
Equations S1 GMA mass equations for pools of total
masses. In these equations, a superscript indicates fluxes for the
complex sphingolipids that were not represented in Figs. 1 and 2 of
the manuscript due to lack of space.
(PDF)
Equations S2 Power-Law terms from Equations S1. In
these equations, a superscript indicates fluxes for the complex
sphingolipids that were not represented in Figs. 1 and 2 of the
manuscript due to lack of space.
(PDF)
Equations S3 GMA mass balance equations for labeled
pools. The structures of the mass balance equations are similar to
the Equations in S8, but for clarity we use dLi=dt instead of
dXi=dt and li,j instead of vi,j .
(PDF)
Equations S4 Terms from Equations S3. A superscript
indicates deviations from the total pool; the method automatically
computes equations for the labeled fractions.
(PDF)
Equations S5 GMA mass balance equations for unla-
beled pools. The structures of the mass balance equations are
similar to the Equations in S8, but for clarity we use dUi=dt
instead of dXi=dt and ui,j instead ofvi,j .
(PDF)
Equations S6 Terms from Equations S5.
(PDF)
Material S1 Mathematical Framework.
(DOC)
Materials S2 Modifications of our former sphingolipid
(SL) model.
(DOC)
Material S3 SL-E GMA model in Plas [48] format. File
used for the dynamic simulations.
(DOC)
Material S4 SL-E flux balanced GMA and Flux aggre-
gated model in Plas [48] format. Files used for total mass
experiments and sensitivity analysis.
(DOC)
Material S5 SL-E GMA model in MatlabH [49] format.
Files used for the dynamic simulations.
(DOC)
Materials S6 SL-E flux balanced GMA model in MatlabH
[49] format. Files used for total mass experiments.
(DOC)
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